Patents Examined by Lynn A. Bristol
  • Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
    Patent number: 10174117
    Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Daniel Baty, Patrick Chames, Brigitte Kerfelec, Marc Turini
  • Compositions and methods for treatment and detection of cancers
    Patent number: 10150818
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 11, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Tsui-Ling Hsu, Yi-Wei Lou, Chih-Wei Lin, Shih-Chi Yeh, Chung-Yi Wu, Han-Chung Wu
  • Method for isolation of soluble polypeptides
    Patent number: 10150807
    Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 11, 2018
    Assignee: National Research Council of Canada
    Inventor: Jamshid Tanha
  • HER2/neu-specific antibodies and methods of using same
    Patent number: 10131713
    Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 20, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
  • Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
    Patent number: 10118969
    Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: November 6, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Che Ma, Han-Chung Wu
  • CD7 nanobodies, encoding sequence and use thereof
    Patent number: 10106609
    Abstract: Provided is a nanometer antibody for human CD7 molecule and an encoding DNA sequence thereof. The nanometer antibody can be efficiently expressed in Escherichia coli, and can be used for preparing an agent for the detection of CD7 molecule and targeted therapy.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: October 23, 2018
    Assignee: PeronGen BioTherapeutics (Suzhou) Co., Ltd.
    Inventors: Lin Yang, Jinle Tang
  • Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
    Patent number: 10106612
    Abstract: Herein is reported a method for producing a bispecific antibody comprising the step of incubating (i) an antibody Fab fragment or a scFv antibody comprising within the 20 C-terminal amino acid residues the amino acid sequence LPX1TG (SEQ ID NO: 01), (ii) a one-armed antibody comprising a full length antibody heavy chain, a full length antibody light chain, and an Fc-heavy chain, whereby the full length antibody heavy chain and the full length antibody light chain are cognate antibody chains that thereof forms an antigen binding site, whereby the full length antibody heavy chain and the Fc-heavy chain are covalently linked to each other via one or more disulfide bonds forming an antibody hinge region, and whereby the Fc-heavy chain has an oligoglycine amino acid sequence at its N-terminus, and (iii) a Sortase A enzyme.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 23, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Sebastian Fenn, Erhard Kopetzki, Georg Tiefenthaler
  • Monoclonal anti-TK1 antibodies
    Patent number: 10100128
    Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 16, 2018
    Assignee: AROCELL AB
    Inventor: Staffan Eriksson
  • Methods for the treatment of vascularizing cancers
    Patent number: 10100115
    Abstract: The invention concerns therapeutic compositions for the treatment of vascularizing cancers, especially, glioblastoma. In particular, the invention is directed to compositions that comprise a molecule having a binding ability that is specific for B7-H3 and a molecule having a binding ability that is specific for a cell-surface factor (or its receptor) that is involved in promoting tumor angiogenesis (especially VEGF or its receptor, VEGFR). The invention is additionally directed to the use of such compositions in the treatment of such cancers, and in particular, in the treatment of glioblastoma.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: October 16, 2018
    Assignee: MacroGenics, Inc.
    Inventor: Andrew S. Chi
  • Stable and soluble antibodies inhibiting TNF alpha
    Patent number: 10100111
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: October 16, 2018
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Leonardo Borras, Tea Gunde, David Urech
  • Humanization of rabbit antibodies using a universal antibody framework
    Patent number: 10087244
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: October 2, 2018
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Leonardo Jose Borras, David Urech
  • Methods for modifying human antibodies by glycan engineering
    Patent number: 10087236
    Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 2, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Fusion protein to target and treat acute myeloid leukemia cells
    Patent number: 10072093
    Abstract: A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: September 11, 2018
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Stefan Barth, Jenny Fitting, Mehmet Kemal Tur
  • Glycans as functional cancer targets and antibodies thereto
    Patent number: 10072073
    Abstract: A glycan having the structure gal?1-3GLcNac?1-3Gal?1-4(Fuc?1-3)GlcNAc (LecLex) which is attached to a lipid or protein backbone, and isolated binding members capable of binding thereto.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: September 11, 2018
    Assignee: The University of Nottingham
    Inventors: Lindy Gillian Durrant, Jiaxin Chua, Tina Rose Parsons
  • Anti-Ly6E antibodies and methods of use
    Patent number: 10066022
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same. In some embodiments, the anti-Ly6E antibodies comprise heavy chain HVRs comprising the amino acid sequences of SEQ ID NOs: 32-34 and/or light chain HVRs comprising the amino acid sequences of SEQ ID NOs: 29-31.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: September 4, 2018
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Antibody constant region variant
    Patent number: 10066018
    Abstract: By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 4, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Hirotake Shiraiwa
  • Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
    Patent number: 10066019
    Abstract: Antibodies of interest comprising a heavy chain signal peptide and/or a light chain signal peptide or combination thereof and compositions are described. The method of determining the signal peptide including creating data set of antibodies signal peptides, clustering, selecting and creating recombinant antibodies for enhanced expression and secretion are described.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: September 4, 2018
    Assignee: Agency for Science, Technology and Research
    Inventor: Zhiwei Song
  • Antibody constructs for CDH19 and CD3
    Patent number: 10059766
    Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: August 28, 2018
    Assignees: AMGEN INC., AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
  • Antibody Fc mutants with ablated effector functions
    Patent number: 10053513
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: August 21, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Stephen McCarthy, Bernard Scallon, Susan Tam, William Strohl, Omid Vafa
  • Sequence dependent aggregation
    Patent number: 10047162
    Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 14, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann